RedHill Biopharma (RDHL) Return on Assets (2016 - 2023)
Historic Return on Assets for RedHill Biopharma (RDHL) over the last 12 years, with Q4 2024 value amounting to 2.94%.
- RedHill Biopharma's Return on Assets rose 35800.0% to 2.94% in Q4 2024 from the same period last year, while for Dec 2024 it was 2.94%, marking a year-over-year increase of 35800.0%. This contributed to the annual value of 711267.64% for FY2024, which is 7112679000.0% down from last year.
- RedHill Biopharma's Return on Assets amounted to 2.94% in Q4 2024, which was up 35800.0% from 2.26% recorded in Q2 2024.
- RedHill Biopharma's Return on Assets' 5-year high stood at 2.94% during Q4 2024, with a 5-year trough of 0.91% in Q3 2022.
- Moreover, its 5-year median value for Return on Assets was 0.24% (2021), whereas its average is 0.11%.
- As far as peak fluctuations go, RedHill Biopharma's Return on Assets crashed by -12300bps in 2022, and later surged by 35800bps in 2024.
- Over the past 5 years, RedHill Biopharma's Return on Assets (Quarter) stood at 0.29% in 2020, then tumbled by -283bps to 0.53% in 2021, then increased by 15bps to 0.45% in 2022, then crashed by -41bps to 0.64% in 2023, then surged by 561bps to 2.94% in 2024.
- Its Return on Assets stands at 2.94% for Q4 2024, versus 2.26% for Q2 2024 and 0.64% for Q4 2023.